Journal article

Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer

Jane Wolstenholme, Francesco Fusco, Alastair M Gray, Joanna Moschandreas, Pradeep S Virdee, Sharon Love, Guy Van Hazel, Peter Gibbs, Harpreet S Wasan, Ricky A Sharma

International Journal of Cancer | WILEY | Published : 2020

Grants

Awarded by Cancer Research UK


Awarded by Bobby Moore Fund of Cancer Research UK


Funding Acknowledgements

The FFr trial was developed by the National Cancer Research Institute Colorectal Clinical Study Group and the NIHR Clinical Research Network and equivalents in devolved nations, and was sponsored by the University of Oxford. The SIRFLOX and FOXFIRE-Global studies were sponsored by Sirtex Technology Pty Ltd. The Centre for Statistics in Medicine, Oxford provided statistical input (supported by Cancer Research UK [grant C5529/A16895]). We thank Georgie Perry and Rhona Atkin for secretarial support. This work was supported by the Bobby Moore Fund of Cancer Research UK (A8971CRUK/07/030) and Sirtex Technology Pty Ltd (FFr, FFrG and SF). A.G. is partly supported by the National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford. The FFrG and SR trials are registered at ClinicalTrials.gov, numbers: NCT01721954 and NCT00724503. The FFr trial is registered at Isrctn.com, number: ISRCTN83867919.